Entrectinib Clinical Trials: Changing the Game with Genetic Testing

STARTRK-2 trial is a currently enrolling trial to test the efficacy and safety of the agent entrectinib which targets 5 abnormalities across a number of cancer sites. 
For Corey Wood, a 25-year-old patient with lung cancer, genetic testing was a “game changer.” Finding out that her tumor was ROS1-positive was the beginning of the path to the rest of her life.

She’s been on entrectinib, an investigational therapy that inhibits certain mutations, leading to tumor shrinkage, for almost two years now. In that time, she’s moved from California to Denver, Colorado, started working full time and is enjoying a more normal life.
"I don’t know where I would be if I wasn’t on targeted therapies,” she said, in an interview with CURE®, arranged by the Bonnie J. Addario Lung Cancer Foundation.

It was reading online forums that introduced Wood to the idea of mutations and targeted therapy — reading about this “miracle therapy.” She went to her oncologist asking about genetic testing, only to find that he had already sent her needle biopsy out to be tested. The results, however, showed that her tumor had tested negative for EGFR, ALK and KRAS, some of the more popular abnormalities.

Her oncologist didn’t give up there. He wanted to test again, and further, for more mutations. Wood said, “All I heard was, ‘You have a chance.’” It required another surgery to get a larger sample and, a few weeks later, the results were in. Wood was ROS1-positive.

“If he [her oncologist] hadn’t said, ‘Maybe we should do another test,’ I don’t think I would have pushed for it, or looked,” Wood said. For many patients, getting that testing is the first step. Pratik Multani, M.D., called it, “the entry into these potential opportunities.”

Talk about this article with other patients, caregivers, and advocates in the Lung Cancer CURE discussion group.
CURE wants to hear from you! We are inviting you to Share Your Story with the readers of CURE. Submit your personal experience with cancer by visiting Share Your Story
Not yet receiving CURE in your mailbox? Sign up to receive CURE Magazine by visiting GetCureNow.com